Literature DB >> 3555651

Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia.

A Raza, Y Maheshwari, H D Preisler.   

Abstract

The proliferative characteristics of myeloid leukemias were defined in vivo after intravenous infusions of bromodeoxyuridine (BrdU) in 40 patients. The percentage of S-phase cells obtained from the biopsies (mean, 20%) were significantly higher (P = .00003) than those determined from the bone marrow (BM) aspirates (mean, 9%). The post-BrdU infusion BM aspirates from 40 patients were incubated with tritiated thymidine in vitro. These double-labeled slides were utilized to determine the duration of S-phase (Ts) in myeloblasts and their total cell cycle time (Tc). The Ts varied from four to 49 hours (mean, 19 hours; median, 17 hours). Similarly, there were wide variations in Tc of individual patients ranging from 16 to 292 hours (mean, 93 hours; median, 76 hours). There was no relationship between Tc and the percentage of S-phase cells, but there was a good correlation between Tc and Ts (r = .8). Patients with relapsed acute nonlymphocytic leukemia (ANLL) appeared to have a longer Ts and Tc than those studied at initial diagnosis. A subgroup of patients at either extreme of Tc were identified who demonstrated clinically documented resistance in response to multiple courses of chemotherapy. We conclude that Ts and Tc provide additional biologic information that may be valuable in understanding the variations observed in the natural history of ANLL.

Entities:  

Mesh:

Year:  1987        PMID: 3555651

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts.

Authors:  U Testa; F Grignani; P Samoggia; C Zanetti; R Riccioni; F Lo Coco; D Diverio; N Felli; C G Passerini; M Grell; P G Pelicci; C Peschle
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

2.  Synergistic decrease of clonal proliferation, induction of differentiation, and apoptosis of acute promyelocytic leukemia cells after combined treatment with novel 20-epi vitamin D3 analogs and 9-cis retinoic acid.

Authors:  E Elstner; M Linker-Israeli; J Le; T Umiel; P Michl; J W Said; L Binderup; J C Reed; H P Koeffler
Journal:  J Clin Invest       Date:  1997-01-15       Impact factor: 14.808

3.  Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.

Authors:  Reda Z Mahfouz; Ania Jankowska; Quteba Ebrahem; Xiaorong Gu; Valeria Visconte; Ali Tabarroki; Pramod Terse; Joseph Covey; Kenneth Chan; Yonghua Ling; Kory J Engelke; Mikkael A Sekeres; Ramon Tiu; Jaroslaw Maciejewski; Tomas Radivoyevitch; Yogen Saunthararajah
Journal:  Clin Cancer Res       Date:  2013-01-03       Impact factor: 12.531

4.  In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity.

Authors:  N Van der Lely; T De Witte; J Wessels; R Raymakers; P Muus; F Preijers
Journal:  Ann Hematol       Date:  1994-05       Impact factor: 3.673

5.  Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor.

Authors:  M Aglietta; W Piacibello; F Sanavio; A Stacchini; F Aprá; M Schena; C Mossetti; F Carnino; F Caligaris-Cappio; F Gavosto
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

6.  The biology of myelodysplastic syndromes: unity despite heterogeneity.

Authors:  Azra Raza; Raymond Cruz; Tahir Latif; Siddhartha Mukherjee; Naomi Galili
Journal:  Hematol Rep       Date:  2010-06-23

7.  Cell kinetics in leukaemia and solid tumours studied with in vivo bromodeoxyuridine and flow cytometry.

Authors:  A Riccardi; M Danova; P Dionigi; P Gaetani; T Cebrelli; G Butti; G Mazzini; G Wilson
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

Review 8.  Cancer cytogenetics: methodology revisited.

Authors:  Thomas S K Wan
Journal:  Ann Lab Med       Date:  2014-10-28       Impact factor: 3.464

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.